Stock market today: S&P 500 ends lower, but tech bounce on dip-buying stems losses
RESEARCH TRIANGLE PARK, N.C. - IQVIA Holdings Inc. (NYSE:IQV) announced Wednesday the appointment of Nobel Prize winner Dr. William G. Kaelin Jr. to its board of directors, effective immediately. The $35.9 billion market cap company, currently trading at $210.1, has seen its shares surge 38.5% over the past six months, approaching its 52-week high of $225.91.
Dr. Kaelin, who received the 2019 Nobel Prize in Physiology or Medicine for his work on oxygen sensing and the von Hippel-Lindau tumor suppressor protein, currently serves as a Senior Physician-Scientist at Brigham and Women’s Hospital in Boston and as the Sidney Farber Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School.
"Bill is a world-renowned scientist and physician with deep expertise in oncology and biomedical innovation," said Ari Bousbib, chairman and CEO of IQVIA, in a press release statement.
In addition to his Nobel Prize, Dr. Kaelin has received numerous scientific honors including the Albert Lasker Basic Medical Research Award and the Canada Gairdner Internal Award. He is also an Investigator at the Howard Hughes Medical Institute and serves on the board of directors of Eli Lilly and Company, where he chairs the Science and Technology Committee.
Dr. Kaelin holds a Doctor of Medicine from Duke University School of Medicine and a Bachelor of Arts in Mathematics and Associate Bachelor in Chemistry from Duke University.
IQVIA provides clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, with approximately 91,000 employees across more than 100 countries.
In other recent news, IQVIA Holdings Inc. reported its third-quarter earnings for 2025, exceeding analyst expectations with an adjusted diluted earnings per share (EPS) of $3.00, compared to the forecast of $2.97. The company’s revenue for the quarter also surpassed expectations, reaching $4.1 billion against a projected $4.08 billion. Despite the positive earnings results, market sentiment appeared cautious. In analyst updates, Baird upgraded IQVIA Holdings from Neutral to Outperform, citing a moderately improving environment in the clinical and commercial research and development sector. The firm also raised its price target to $258.00 from $224.00. Conversely, TD Cowen downgraded IQVIA from Buy to Hold, while raising its price target to $215.00 from $206.00, due to valuation concerns. In other developments, NEXT Oncology, an Avacare business, has expanded its Phase I cancer clinical trial services to Asia through a partnership with Kansai Medical University in Osaka, Japan. This collaboration marks Osaka as the latest addition to NEXT Oncology’s global network.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.